Brokerages Set GoodRx Holdings, Inc. (NASDAQ:GDRX) Target Price at $3.81

Shares of GoodRx Holdings, Inc. (NASDAQ:GDRX) have earned a consensus rating of “Hold” from the fifteen research firms that are presently covering the firm, MarketBeat reports. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $3.8125.

A number of research firms have weighed in on GDRX. Wells Fargo & Company dropped their target price on shares of GoodRx from $7.00 to $3.50 and set an “overweight” rating on the stock in a research note on Wednesday, March 4th. Citigroup boosted their price target on shares of GoodRx from $3.50 to $4.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. The Goldman Sachs Group reissued a “neutral” rating and issued a $3.50 price target on shares of GoodRx in a research report on Friday, May 8th. TD Cowen boosted their price target on shares of GoodRx from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, May 11th. Finally, Weiss Ratings lowered shares of GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday, May 20th.

GoodRx Stock Up 5.0%

GDRX opened at $2.83 on Thursday. The company has a quick ratio of 1.47, a current ratio of 1.47 and a debt-to-equity ratio of 0.78. The stock has a market cap of $967.76 million, a price-to-earnings ratio of 47.09, a PEG ratio of 1.30 and a beta of 1.61. GoodRx has a twelve month low of $1.77 and a twelve month high of $5.81. The company’s 50-day moving average price is $2.62 and its two-hundred day moving average price is $2.48.

GoodRx (NASDAQ:GDRX) last released its earnings results on Wednesday, May 6th. The company reported $0.07 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.07. The firm had revenue of $194.01 million for the quarter, compared to analysts’ expectations of $185.40 million. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The company’s quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.09 earnings per share. As a group, equities analysts expect that GoodRx will post 0.17 earnings per share for the current year.

Institutional Trading of GoodRx

Several hedge funds and other institutional investors have recently modified their holdings of GDRX. LSV Asset Management increased its holdings in GoodRx by 20.0% during the 4th quarter. LSV Asset Management now owns 2,825,900 shares of the company’s stock worth $7,658,000 after acquiring an additional 471,319 shares during the period. Nano Cap New Millennium Growth Fund L P bought a new stake in GoodRx during the 4th quarter worth approximately $1,585,000. Northwestern Mutual Wealth Management Co. increased its holdings in GoodRx by 10,242.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 1,502,666 shares of the company’s stock worth $4,072,000 after acquiring an additional 1,488,137 shares during the period. Prescott Group Capital Management L.L.C. bought a new stake in GoodRx during the 4th quarter worth approximately $4,812,000. Finally, Boothbay Fund Management LLC bought a new stake in GoodRx during the 3rd quarter worth approximately $43,000. Institutional investors own 63.77% of the company’s stock.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.